We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 458

DOJ Trial Machine is Staffed Up, Fired Up
  • McDermott Will & Emery
  • USA
  • February 8 2017

The DOJ Antitrust Division scored another trial win this time in a real estate foreclosure bid rigging case. Yesterday’s win follows


Merger control: gun jumping goes global
  • McDermott Will & Emery
  • European Union, USA
  • June 28 2010

Broadly defined, "gun jumping" refers to unlawful premerger coordination between the parties to an M&A transaction


2017 Intellectual Property Law Year In Review
  • McDermott Will & Emery
  • USA
  • January 31 2017

In a year where politics dominated the headlines, intellectual property law still captured a share of the nation's spotlight. 2016 brought big


The top five (avoidable) antitrust traps in M&A transactions
  • McDermott Will & Emery
  • USA
  • February 28 2011

In M&A transactions, the parties are often focused on negotiating the transfer of assets or equity, and may treat antitrust as a mere procedural milestone


Massachusetts Court Weighs in on Product Hopping Allegations and Reverse Payment Standing
  • McDermott Will & Emery
  • USA
  • November 11 2016

Addressing a motion to dismiss a bevy of antitrust allegations, the US District Court for the District of Massachusetts held that a class of


‘Sham litigation’ sufficiently plead when generic provides detailed statement and access to ANDA
  • McDermott Will & Emery
  • USA
  • October 30 2015

Explaining the differences between the pleading standards for antitrust and patent misuse defenses, the U.S. District Court for the District of New


US and EU Requirements for Pre-Merger Notification of an Acquisition of a Minority Shareholding Interest
  • McDermott Will & Emery
  • European Union, USA
  • August 8 2016

In May, the Federal Trade Commission (FTC) required Hikma Pharmaceuticals PLC to divest its 23 percent interest in Unimark Remedies, Ltd. and its US


Change in LBO Valuation for HSR Purposes
  • McDermott Will & Emery
  • USA
  • October 13 2016

The Federal Trade Commission (FTC) recently reversed its position on how to calculate the size-of-transaction for HSR purposes in connection with


Flurry of Antitrust Merger Enforcement Actions as Obama Presidency Comes to a Close
  • McDermott Will & Emery
  • USA
  • February 2 2017

The Federal Trade Commission (FTC) and Antitrust Division of the Department of Justice (DOJ) announced several antitrust enforcement actions in


No presumption, but inference of irreparable harm permissible under Lanham Act
  • McDermott Will & Emery
  • USA
  • January 29 2015

Addressing interpretation of advertising claims when the packaging or label unambiguously defines a claim term and an inference of irreparable harm